French pharma Sanofi has acquired the U.S.-based biotech firm Vigil Neuroscience for $470 million, aiming to bolster its ...

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which ...

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.

Part of the deal also includes an additional $2 cash payment per share upon the first commercial sale of Vigil’s Alzheimer’s ...

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

Sanofi (NASDAQ:SNY) said Wednesday it agreed to acquire clinical-stage biotechnology company Vigil Neuroscience (NASDAQ:VIGL) ...

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's ...

Paris: Sanofi has announced that it has entered into an agreement to acquire Vigil Neuroscience, Inc., a publicly traded ...

About a year after investing in Vigil Neuroscience Inc., Sanofi is now acquiring the Watertown biotech and its treatment in ...